Study to Evaluate the Safety and Efficacy of Sirolimus, in Subject With Refractory Solid Tumors
Status:
Recruiting
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
This study is a single arm, pilot study of sirolimus in patient with
Phosphatidylinositide-3-kinase (PIK3CA) mutation, PIK3CA amplification , PIK3CA-AKT pathway
aberration Refractory solid tumor and/or specific sensitivity to mTOR inhibitors by Avatar
scan that has progressed following standard therapy or that has not responded to standard
therapy or for which there is no standard therapy.
sirolimus 1mg will be administered orally daily. To investigate the efficacy and safety of
sirolimus in patient with Refractory solid tumor.